CRISPR Therapeutics (CRSP) News Today $47.88 +1.59 (+3.43%) (As of 11/22/2024 ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street TipRanks The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 Time Period CRISPR Therapeutics AG (CRSP) Jefferies London Healthcare Conference (Transcript)November 20 at 10:06 PM | seekingalpha.comTruist Financial Keeps Their Buy Rating on Crispr Therapeutics AG (CRSP)November 20 at 11:59 AM | markets.businessinsider.comCRISPR Therapeutics AG (CRSP): Among the Best Genomics Stocks to Buy Right NowNovember 20 at 11:59 AM | yahoo.comCRISPR Therapeutics AG (NASDAQ:CRSP) Sees Large Increase in Short InterestCRISPR Therapeutics AG (NASDAQ:CRSP - Get Free Report) saw a significant increase in short interest in the month of October. As of October 31st, there was short interest totalling 18,590,000 shares, an increase of 5.7% from the October 15th total of 17,590,000 shares. Based on an average daily trading volume, of 1,160,000 shares, the short-interest ratio is currently 16.0 days.November 19, 2024 | marketbeat.comCrispr Therapeutics management to meet with Piper SandlerNovember 19, 2024 | markets.businessinsider.comCathie Wood’s ARK Investment bought 176K shares of Crispr Therapeutics todayNovember 19, 2024 | markets.businessinsider.comDeciphering Disruption: Inside Cathie Wood's Latest Plays (CRSP)Cathie Wood's recent stock market activity offers a glimpse into her evolving investment strategy and the potential of disruptive technologies.November 18, 2024 | marketbeat.com2 Top Biotech Stocks to Buy Now and Hold For 5 Years or MoreNovember 16, 2024 | fool.comCathie Wood’s ARK Investment bought 178.1K shares of Crispr Therapeutics todayNovember 15, 2024 | markets.businessinsider.comCRISPR Therapeutics AG (CRSP) Guggenheim Inaugural Healthcare Innovation Conference (Transcript)November 15, 2024 | seekingalpha.comWhere Will CRISPR Therapeutics Be in 3 Years?November 15, 2024 | fool.comCRISPR Therapeutics to Present at the Jefferies London Healthcare ConferenceNovember 14, 2024 | globenewswire.comSamarth Kulkarni Sells 30,000 Shares of CRISPR Therapeutics AG (NASDAQ:CRSP) StockNovember 14, 2024 | insidertrades.comCRISPR Therapeutics AG (NASDAQ:CRSP) Shares Sold by Van ECK Associates CorpVan ECK Associates Corp trimmed its position in shares of CRISPR Therapeutics AG (NASDAQ:CRSP - Free Report) by 98.1% in the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 1,546 shares of the company's stock afterNovember 14, 2024 | marketbeat.com3 Unstoppable Growth Stocks I'm Loading $25,000 Each Into by 2029November 13, 2024 | fool.comSumitomo Mitsui Trust Group Inc. Cuts Holdings in CRISPR Therapeutics AG (NASDAQ:CRSP)Sumitomo Mitsui Trust Group Inc. lessened its position in shares of CRISPR Therapeutics AG (NASDAQ:CRSP - Free Report) by 5.8% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 2,968,034 shares of the companNovember 13, 2024 | marketbeat.comBaillie Gifford & Co. Reduces Stake in CRISPR Therapeutics AG (NASDAQ:CRSP)Baillie Gifford & Co. decreased its stake in shares of CRISPR Therapeutics AG (NASDAQ:CRSP - Free Report) by 10.0% during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 364,768 shares of the company's stock afterNovember 13, 2024 | marketbeat.comCrispr Therapeutics Q3 Earnings: No Casgevy Revenue, But Plenty Of OptimismNovember 11, 2024 | seekingalpha.comChardan Capital Issues Optimistic Estimate for CRSP EarningsCRISPR Therapeutics AG (NASDAQ:CRSP - Free Report) - Chardan Capital boosted their FY2024 earnings per share (EPS) estimates for CRISPR Therapeutics in a report issued on Wednesday, November 6th. Chardan Capital analyst Y. Livshits now forecasts that the company will post earnings of ($4.84) perNovember 11, 2024 | marketbeat.comCathie Wood Goes Bargain Hunting: 3 Stocks She Just BoughtNovember 8, 2024 | fool.comCRISPR Therapeutics AG (NASDAQ:CRSP) Just Released Its Third-Quarter Results And Analysts Are Updating Their EstimatesNovember 8, 2024 | finance.yahoo.comCrispr Therapeutics AG: Hold Rating Amidst Modest Growth and Awaited Pipeline CatalystsNovember 8, 2024 | markets.businessinsider.comCRSP FY2024 EPS Lowered by Brookline Capital ManagementCRISPR Therapeutics AG (NASDAQ:CRSP - Free Report) - Stock analysts at Brookline Capital Management reduced their FY2024 earnings per share estimates for shares of CRISPR Therapeutics in a research report issued on Tuesday, November 5th. Brookline Capital Management analyst L. Cann now forecastsNovember 8, 2024 | marketbeat.comFY2024 Earnings Estimate for CRSP Issued By Leerink PartnrsCRISPR Therapeutics AG (NASDAQ:CRSP - Free Report) - Investment analysts at Leerink Partnrs lifted their FY2024 earnings per share estimates for CRISPR Therapeutics in a research note issued on Tuesday, November 5th. Leerink Partnrs analyst M. Foroohar now expects that the company will earn ($5.4November 8, 2024 | marketbeat.comCRISPR Therapeutics AG (NASDAQ:CRSP) Position Reduced by ARK Investment Management LLCARK Investment Management LLC trimmed its stake in shares of CRISPR Therapeutics AG (NASDAQ:CRSP - Free Report) by 3.6% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 7,498,625 shares of the company'sNovember 8, 2024 | marketbeat.comCRISPR Therapeutics AG (NASDAQ:CRSP) Receives Consensus Rating of "Hold" from BrokeragesShares of CRISPR Therapeutics AG (NASDAQ:CRSP - Get Free Report) have been given an average recommendation of "Hold" by the nineteen ratings firms that are covering the company, Marketbeat reports. Two research analysts have rated the stock with a sell recommendation, eight have issued a hold recoNovember 8, 2024 | marketbeat.comCRISPR Therapeutics (NASDAQ:CRSP) Upgraded by StockNews.com to "Sell" RatingStockNews.com upgraded shares of CRISPR Therapeutics to a "sell" rating in a research note on Thursday.November 7, 2024 | marketbeat.comCrispr Therapeutics AG: Balancing Positive Momentum and Uncertain Revenue TrajectoryNovember 6, 2024 | markets.businessinsider.comCrispr Therapeutics price target lowered to $55 from $59 at BarclaysNovember 6, 2024 | msn.comTruist Financial Remains a Buy on Crispr Therapeutics AG (CRSP)November 6, 2024 | markets.businessinsider.comBarclays Remains a Hold on Crispr Therapeutics AG (CRSP)November 6, 2024 | markets.businessinsider.comCrispr Therapeutics AG (CRSP) Receives a Hold from Evercore ISINovember 6, 2024 | markets.businessinsider.comBarclays Issues Pessimistic Forecast for CRISPR Therapeutics (NASDAQ:CRSP) Stock PriceBarclays cut their price objective on CRISPR Therapeutics from $59.00 to $55.00 and set an "equal weight" rating on the stock in a research report on Wednesday.November 6, 2024 | marketbeat.comNeedham & Company LLC Reiterates Buy Rating for CRISPR Therapeutics (NASDAQ:CRSP)Needham & Company LLC reaffirmed a "buy" rating and set a $84.00 price target on shares of CRISPR Therapeutics in a research note on Wednesday.November 6, 2024 | marketbeat.comCRISPR Therapeutics AG: CRISPR Therapeutics Provides Business Update and Reports Third Quarter 2024 Financial ResultsNovember 6, 2024 | finanznachrichten.deCrispr Therapeutics AG: Strategic Advancements and Strong Financial Position Justify Buy RatingNovember 6, 2024 | markets.businessinsider.comCRISPR Therapeutics Advances with Solid Financials and ApprovalsNovember 6, 2024 | markets.businessinsider.comPromising Pipeline and Successful Product Launches Boost Crispr Therapeutics’ Buy RatingNovember 6, 2024 | markets.businessinsider.comCrispr Therapeutics AG: Strong Financials and Innovative Therapies Drive a Compelling Buy RecommendationNovember 6, 2024 | markets.businessinsider.comCRISPR Therapeutics (NASDAQ:CRSP) Stock Price Down 4% - Here's WhyCRISPR Therapeutics (NASDAQ:CRSP) Shares Down 4% - Here's WhyNovember 5, 2024 | marketbeat.comCRISPR Therapeutics Provides Business Update and Reports Third Quarter 2024 Financial ResultsNovember 5, 2024 | globenewswire.comInternational Assets Investment Management LLC Invests $1.83 Million in CRISPR Therapeutics AG (NASDAQ:CRSP)International Assets Investment Management LLC bought a new position in shares of CRISPR Therapeutics AG (NASDAQ:CRSP - Free Report) during the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor bought 38,852 shares of the company's stNovember 4, 2024 | marketbeat.comThinking of Buying CRISPR Therapeutics Stock? Watch These 2 Key NumbersNovember 2, 2024 | fool.comCapital Advisors Inc. OK Purchases 22,583 Shares of CRISPR Therapeutics AG (NASDAQ:CRSP)Capital Advisors Inc. OK grew its holdings in shares of CRISPR Therapeutics AG (NASDAQ:CRSP - Free Report) by 8.1% in the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 300,589 shares of the company's stock after purchasing an addiNovember 2, 2024 | marketbeat.comCRISPR Therapeutics (NASDAQ:CRSP) Trading 7.2% Higher - Here's What HappenedCRISPR Therapeutics (NASDAQ:CRSP) Trading Up 7.2% - Here's What HappenedNovember 1, 2024 | marketbeat.comIs CRISPR Therapeutics (CRSP) a Promising Gene Editing Stock?October 31, 2024 | msn.comCrispr Therapeutics: Avoid Catching The Falling Knife This Time (Downgrade)October 30, 2024 | seekingalpha.com12 High-Growth Stocks That Could Deliver Parabolic ReturnsOctober 28, 2024 | fool.comThe Ultimate Biotech Stock to Buy With $50 Right NowOctober 26, 2024 | fool.comCathie Wood’s ARK Investment bought 47.8K shares of Crispr Therapeutics todayOctober 23, 2024 | markets.businessinsider.com Get CRISPR Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CRSP and its competitors with MarketBeat's FREE daily newsletter. Email Address [625,000% Gain] – Are You Ready for the Next Altcoin Boom? (Ad)All of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you know anything about crypto, you know that altcoin seasons are where some of the biggest gains happen. Register for the FREE Workshop Now & get $10 in Bitcoin CRSP Media Mentions By Week CRSP Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. CRSP News Sentiment▼0.380.49▲Average Medical News Sentiment CRSP News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. CRSP Articles This Week▼810▲CRSP Articles Average Week Get CRISPR Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CRSP and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Allogene Therapeutics News Sangamo Therapeutics News Fate Therapeutics News Adverum Biotechnologies News Cellectis News bluebird bio News Precision BioSciences News Moderna News Neurocrine Biosciences News Bio-Techne News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:CRSP) was last updated on 11/23/2024 by MarketBeat.com Staff From Our PartnersMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | Sponsored⭕ [URGENT] Buy Alert just triggeredMy absolute favorite stock just hit a critical "buy now" trigger price.Behind the Markets | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe pin that pops the AI bubbleMy new documentary explores the background to this pattern and how and why I believe it will almost certainly ...Porter & Company | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding CRISPR Therapeutics AG Please log in to your account or sign up in order to add this asset to your watchlist. Share CRISPR Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
